Wider Access To Naloxone Overdose Medication On Tap In Meeting
This article was originally published in The Tan Sheet
Executive Summary
Behind-the-counter placement of opioid overdose treatment does not resonate with FDA, even as it wants to broaden availability. Naloxone administration has increased among non-medical personnel, which may be a reason FDA wants to discuss broader use of the product.
You may also be interested in...
Rescue Medicine Switch Concept Draws Criticism
FDA considers switching some prescription “antidotes” to restricted nonprescription status so consumers who can self-identify their need for the drugs and who previously had a prescription can easily access them during life-threatening events, says CDER Director Janet Woodcock.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.